Department of Cardiovascular Diseases, Mayo Clinic, 200 First Street SW, Rochester, MN 55902, USA.
Cardiol Clin. 2019 Nov;37(4):365-384. doi: 10.1016/j.ccl.2019.07.003. Epub 2019 Aug 26.
The introduction of targeted agents into modern cancer therapy pursued the goal of molecularly more specific, and thereby more effective and safer, therapies. Paradoxically, however, several toxicities were brought to greater attention, among these not only cardiac but also vascular toxicities. The latter reach far beyond venous thromboembolism and include a broad spectrum of presentations based on the vascular territories and pathomechanisms involved, including abnormal vascular reactivity, acute thrombosis, or accelerated atherosclerosis. This article provides an overview of the most common presentations and their management strategies.
靶向药物在现代癌症治疗中的引入旨在追求更具分子特异性的治疗方法，从而实现更有效和更安全的治疗效果。然而，具有讽刺意味的是，一些毒性作用引起了更多的关注，其中不仅包括心脏毒性，还包括血管毒性。后者的范围远远超出了静脉血栓栓塞症，包括基于所涉及的血管区域和病理机制的广泛表现形式，包括血管反应异常、急性血栓形成或加速动脉粥样硬化。本文概述了最常见的表现形式及其管理策略。
